The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.
Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.